Ryan Berry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ryan Berry has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Chadi Alraies
Detroit Medical Center Detroit Michigan USA
5 shared publications - Yasemin Bahar
Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, USA
3 shared publications - Alaa Roto
Department of Internal Medicine, DMC Sinai Grace, Wayne State School of Medicine, Detroit, USA
2 shared publications - Mohammad Hamza
Department of Internal Medicine, Albany Medical Center, Albany, NY 12208, USA
2 shared publications - Yasar Sattar
Department of Cardiology West Virginia University Morgantown West Virginia USA
2 shared publications - Zohaib Khan
Department of Internal Medicine, DMC Sinai Grace, Wayne State School of Medicine, Detroit, USA
2 shared publications
Latest Publications
- 30 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Impella in Cardiogenic Shock: An Updated Meta-Analysis
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
- 30 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
Impella in Cardiogenic Shock: An Updated Meta-Analysis
Despite technological advancements, mortality remains high in patients with myocardial infarction complicated by cardiogenic shock. Impella is increasingly used as an adjunct to standard treatment due to its hemodynamic benefits, though mixed study results limit its adoption. This meta-analysis aims to clarify Impella’s efficacy by focusing on high-quality data from RCTs and cohort studies. A comprehensive literature search was conducted for randomized controlled trials and cohort studies comparing Impella with intra-aortic balloon pump (IABP) and extracorporeal membrane oxygenation (ECMO). Assessed metrics included mortality, clinical events, and hematologic markers. Data was analyzed using the Mantel-Haenszel random-effects model. Of 787 articles, 12 studies (4918 patients) met the inclusion criteria. Impella groups showed significant increases in thrombosis risk (RR: 4.94) and had a higher bleeding risk compared to IABP (RR: 1.98) but a lower risk compared to ECMO (RR: 0.66). All other comparisons did not reach statistical significance. Despite updated data and a stringent quality threshold, the hemodynamic benefits of Impella and the device’s risk of thrombosis and bleeding were high. Future trials should emphasize patient selection, timing of placement, and operator proficiency to evaluate Impella’s efficacy and safety better.
- 30 July 2025
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 25 (5) , 729-730
Authors’ Reply to Umińska and Fabiszak: ‘Morphine and P2Y12 inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis’
- 30 July 2025
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 25 (5) , 729-730
Authors’ Reply to Umińska and Fabiszak: ‘Morphine and P2Y12 inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis’
- 29 April 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 40 (15) , 3694-3704
Impact of Mental Health Disorders in Patients with Myocardial Infarction with Non-obstructive Coronary Arteries: A Propensity Score–Matched Nationwide Analysis
Background Myocardial infarction with non-obstructive coronary arteries (MINOCA) is defined by myocardial infarction criteria with < 50% stenosis and no clear cause. While mental health disorders are linked to cardiovascular risk, their impact on MINOCA outcomes is not well studied. Methods We conducted a retrospective cohort study using the National Inpatient Sample (NIS) from 2017 to 2021, identifying hospitalized MINOCA patients with and without mental health disorders using ICD-10-CM codes. Propensity score matching and inverse probability weighting (IPW) were employed to adjust for confounders and balance baseline characteristics. Multivariable logistic regression estimated adjusted odds ratios and 95% confidence intervals for in-hospital outcomes. Results Among 4300 propensity-matched pairs (8600 patients), MINOCA patients with mental health disorders had higher in-hospital mortality (2.26% vs 1.21%, p < 0.001) and increased risk of sudden cardiac arrest (1.51% vs 0.65%, p < 0.001). They were also more likely to develop pulmonary embolism (1.54% vs 0.65%, p < 0.001) and acute kidney injury (25.45% vs 20.24%, p < 0.001). Conclusion Mental health disorders are independently associated with higher in-hospital mortality and adverse cardiovascular outcomes among MINOCA patients. These findings highlight the urgent need for integrated cardiovascular and psychiatric care, emphasizing early screening, multidisciplinary management, and targeted interventions to improve patient outcomes. Graphical Abstract
- 29 April 2025
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 40 (15) , 3694-3704
Impact of Mental Health Disorders in Patients with Myocardial Infarction with Non-obstructive Coronary Arteries: A Propensity Score–Matched Nationwide Analysis
Background Myocardial infarction with non-obstructive coronary arteries (MINOCA) is defined by myocardial infarction criteria with < 50% stenosis and no clear cause. While mental health disorders are linked to cardiovascular risk, their impact on MINOCA outcomes is not well studied. Methods We conducted a retrospective cohort study using the National Inpatient Sample (NIS) from 2017 to 2021, identifying hospitalized MINOCA patients with and without mental health disorders using ICD-10-CM codes. Propensity score matching and inverse probability weighting (IPW) were employed to adjust for confounders and balance baseline characteristics. Multivariable logistic regression estimated adjusted odds ratios and 95% confidence intervals for in-hospital outcomes. Results Among 4300 propensity-matched pairs (8600 patients), MINOCA patients with mental health disorders had higher in-hospital mortality (2.26% vs 1.21%, p < 0.001) and increased risk of sudden cardiac arrest (1.51% vs 0.65%, p < 0.001). They were also more likely to develop pulmonary embolism (1.54% vs 0.65%, p < 0.001) and acute kidney injury (25.45% vs 20.24%, p < 0.001). Conclusion Mental health disorders are independently associated with higher in-hospital mortality and adverse cardiovascular outcomes among MINOCA patients. These findings highlight the urgent need for integrated cardiovascular and psychiatric care, emphasizing early screening, multidisciplinary management, and targeted interventions to improve patient outcomes. Graphical Abstract
- Open Access
- 1 April 2025
- Published by MDPI AG in Complications
- Vol. 2 (2) , 9
The Impact of Periprocedural Prosthetic Valve Leak After Transcatheter Aortic Valve Implantation
A periprocedural prosthetic valve leak (PVL) after transcatheter aortic valve implantation (TAVI), a minimally invasive treatment modality for patients with severe, symptomatic aortic stenosis, may entail serious morbidity. Cohorts hospitalized for TAVI from a national database (2016–2020) were stratified on the presence of PVL post-TAVI. TAVI patients with and without PVL were selected for propensity score matching. Pearson’s x2 test was used to compare outcomes. Among 319,448 TAVI patients over five years, 2043 had periprocedural PVL identified at index hospitalization, acute heart failure (49.61% vs. 41.15%, p < 0.001), acute kidney injury (20.40% vs. 11.77%, p < 0.001), cardiac tamponade (1.31% vs. 0.52%, p < 0.05), higher inpatient mortality (3.05% vs. 1.05%, p < 0.001), postprocedural bleeding (3.5% vs. 1.48%, p < 0.001), sudden cardiac arrest (15.34% vs. 8.54%, p < 0.001), and vascular complications (4.10% vs. 1.57%, p < 0.001). TAVI with PVL was associated with a significantly longer length of stay (p < 0.05) and total cost of hospitalization (p < 0.05). The 30-day (15.2% vs. 12%, p = 0.02), 90-day (24.4% vs. 19.9%, p < 0.01), and 180-day (34.7% vs. 24.8%, p < 0.01) readmission rates were significantly higher in the TAVI cohort with PVL. PVL in patients post-TAVI is associated with greater mortality and morbidity during index hospitalization, higher readmission rates, and increased burden on healthcare costs and infrastructure.
- 1 April 2025
- Published by MDPI AG in Complications
- Vol. 2 (2) , 9
Open AccessThe Impact of Periprocedural Prosthetic Valve Leak After Transcatheter Aortic Valve Implantation
A periprocedural prosthetic valve leak (PVL) after transcatheter aortic valve implantation (TAVI), a minimally invasive treatment modality for patients with severe, symptomatic aortic stenosis, may entail serious morbidity. Cohorts hospitalized for TAVI from a national database (2016–2020) were stratified on the presence of PVL post-TAVI. TAVI patients with and without PVL were selected for propensity score matching. Pearson’s x2 test was used to compare outcomes. Among 319,448 TAVI patients over five years, 2043 had periprocedural PVL identified at index hospitalization, acute heart failure (49.61% vs. 41.15%, p < 0.001), acute kidney injury (20.40% vs. 11.77%, p < 0.001), cardiac tamponade (1.31% vs. 0.52%, p < 0.05), higher inpatient mortality (3.05% vs. 1.05%, p < 0.001), postprocedural bleeding (3.5% vs. 1.48%, p < 0.001), sudden cardiac arrest (15.34% vs. 8.54%, p < 0.001), and vascular complications (4.10% vs. 1.57%, p < 0.001). TAVI with PVL was associated with a significantly longer length of stay (p < 0.05) and total cost of hospitalization (p < 0.05). The 30-day (15.2% vs. 12%, p = 0.02), 90-day (24.4% vs. 19.9%, p < 0.01), and 180-day (34.7% vs. 24.8%, p < 0.01) readmission rates were significantly higher in the TAVI cohort with PVL. PVL in patients post-TAVI is associated with greater mortality and morbidity during index hospitalization, higher readmission rates, and increased burden on healthcare costs and infrastructure.
- 19 December 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 25 (3) , 389-398
Morphine and P2Y12 Inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis
Background Morphine is used to control pain in ST-elevation myocardial infarction but reduces P2Y12 inhibition. It is not known if this modulation of platelet inhibition appreciably affects clinical outcomes. Methods We screened 979 articles and identified seven studies that met the eligibility criteria for meta-analysis. Outcomes included 11 metrics across angiographic and clinical domains. A random effects model assessed heterogeneity between studies. Results The opiate group showed decreased achievement of postprocedural thrombolysis in myocardial infarction (TIMI) 2 flow relative to placebo [risk ratio (RR) 0.71, 95% confidence interval (CI) 0.52–0.97, p = 0.03, I2 = 0.0%]. All other metrics listed below showed no statistically significant difference between groups: infarct size, microvascular obstruction, microvascular/salvage index, absence of pre- percutaneous coronary intervention (PCI) TIMI 3 flow, postprocedural TIMI 2 flow, postprocedural TIMI 3 flow, all-cause mortality, stroke, repeat MI, unstable angina, and left ventricular ejection fraction. However, there were no statistically significant differences in infarct size [odds ratio (OR) − 0.12, 95% CI − 0.37 to 0.17, p = 0.42], microvascular obstruction [standard mean difference (SMD) = 0.02, 95% CI − 0.12 to 0.16, p = 0.82], microvascular obstruction/salvage index (SMD = − 0.05, 95% CI − 0.24 to 0.13, p = 0.57), absence of pre-PCI TIMI 3 flow (OR 0.98, 95% CI 0.79–1.22, p = 0.87), and postprocedural TIMI 3 flow (OR 1.23, 95% CI 0.84–1.79, p = 0.28) between the two groups. Conclusions In STEMI, opiates correlate with worse angiographic outcomes, specifically postprocedural TIMI 2 flow. However, this observation does not appear to be clinically consequential.
- 19 December 2024
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 25 (3) , 389-398
Morphine and P2Y12 Inhibitors in ST-Elevation Myocardial Infarction: An Updated Meta-Analysis
Background Morphine is used to control pain in ST-elevation myocardial infarction but reduces P2Y12 inhibition. It is not known if this modulation of platelet inhibition appreciably affects clinical outcomes. Methods We screened 979 articles and identified seven studies that met the eligibility criteria for meta-analysis. Outcomes included 11 metrics across angiographic and clinical domains. A random effects model assessed heterogeneity between studies. Results The opiate group showed decreased achievement of postprocedural thrombolysis in myocardial infarction (TIMI) 2 flow relative to placebo [risk ratio (RR) 0.71, 95% confidence interval (CI) 0.52–0.97, p = 0.03, I2 = 0.0%]. All other metrics listed below showed no statistically significant difference between groups: infarct size, microvascular obstruction, microvascular/salvage index, absence of pre- percutaneous coronary intervention (PCI) TIMI 3 flow, postprocedural TIMI 2 flow, postprocedural TIMI 3 flow, all-cause mortality, stroke, repeat MI, unstable angina, and left ventricular ejection fraction. However, there were no statistically significant differences in infarct size [odds ratio (OR) − 0.12, 95% CI − 0.37 to 0.17, p = 0.42], microvascular obstruction [standard mean difference (SMD) = 0.02, 95% CI − 0.12 to 0.16, p = 0.82], microvascular obstruction/salvage index (SMD = − 0.05, 95% CI − 0.24 to 0.13, p = 0.57), absence of pre-PCI TIMI 3 flow (OR 0.98, 95% CI 0.79–1.22, p = 0.87), and postprocedural TIMI 3 flow (OR 1.23, 95% CI 0.84–1.79, p = 0.28) between the two groups. Conclusions In STEMI, opiates correlate with worse angiographic outcomes, specifically postprocedural TIMI 2 flow. However, this observation does not appear to be clinically consequential.